Want to see GPCR full AI Analyst Report?
GPCR Stock Chart & Stats
$49.12
-$1.68(-3.31%)
At close: 4:00 PM EDT
$49.12
-$1.68(-3.31%)
Day’s Range― - ―
52-Week Range$17.52 - $94.90
Previous CloseN/A
Volume655.41K
Average Volume (3M)749.96K
Market Cap
$3.83B
Enterprise Value$2.56K
Total Cash (Recent Filing)$1.34B
Total Debt (Recent Filing)$6.23M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 18, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.03
Shares Outstanding71,309,860
10 Day Avg. Volume595,420
30 Day Avg. Volume749,963
Financial Highlights & Ratios
PEG Ratio-11.30
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$109.33Price Target Upside122.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.63
Revenue Forecast (FY)$41.67M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low debt-to-equity (~0.4%) and sizable equity provide durable financial flexibility, lowering refinancing risk and supporting multi-year R&D funding. This cushion enables the company to advance late-stage programs without immediate pressure to cut development spending.
Cash Runway / FundingA ~ $1.5B cash position expected to fund operations through 2028 materially lengthens runway for pivotal trials. This reduces near-term financing needs, allowing management to execute Phase 3 planning and invest in competitive program expansion with less immediate dilution risk.
Clinical Progress & Strategic FocusRobust Phase 2 results and constructive FDA end-of-Phase-2 feedback materially de‑risk the development pathway. Coupled with an oral GPCR small-molecule strategy targeting obesity, this creates a structural opportunity to compete vs injectable therapies if Phase 3 confirms efficacy and safety.
Bears Say
High Cash BurnSustained and growing negative free cash flow (~-$210M TTM) means the business consumes significant capital to fund R&D. Long-term reliance on external financing raises execution risk and can constrain strategic optionality if capital markets tighten.
Pre-revenue ModelThe company remains pre-revenue with widening operating and net losses. Without product revenues, profitability depends entirely on successful trial outcomes and future commercialization, amplifying funding needs and making returns contingent on binary development events.
Dilution Risk From Expanded ATMRemoval of the ATM cap and $400M capacity enhances financing optionality but raises structural dilution risk. In a pre-revenue biotech, recurring equity issuance to fund development can erode shareholder ownership and pressure per-share economics over time.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $17.52 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $3.83B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Nov 18, 2026 which is in 98 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Aug 06, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.436 by -$0.054.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.32.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 71,309,860 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.436. Following the earnings report the stock price went up 0.988%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$109.33 (122.58% Upside)
$109.33 (122.58% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 475.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 91%
Bearish news 9%
Bearish news 9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
171.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
74.04%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$109.33
▲(122.58% Upside)
Technical Analysis
Ownership Overview
10.24% Insiders
26.20% Mutual Funds
1.52% Other Institutional Investors
60.73% Public Companies and Individual Investors